Authors: ANTHONY TSARBOPOULOS
Mass Spectrometry (MS) has played an important role in the design, discovery and development of new pharmaceuticals, from the earliest stages of disease determination through the final stages of clinical testing. LCMS and LC-MS/MS assays are the methods of choice for the late-stage discovery studies because they are rapid, sensitive, easy to automate and robust. The introduction of electrospray ionization (ESI) and matrix-assisted laser desorption/ionization (MALDI) methods combined with the rapid proliferation of several types of mass analyzers has revolutionized the applicability of MS for studying proteins of high molecular weights by themselves or when they are bound to ligands. In this presentation, complete structural analysis of recombinant protein pharmaceuticals and MS identification of PTMs, along with ESI MS screening of putative inhibitors for proteins responsible for certain diseases will be illustrated.
Keywords: Mass Spectrometry, Proteins, Post-translational Modifications, Alzheimer’s Disease, beta amyloid peptide